Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-60
SponsorLindenwood University
About this trial
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.
Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.
Eligibility criteria
Qualifiers
Between 30 and 60 years old.
Body mass index values will range from >18.5 and <29.9 kg/m2
Subject agrees to maintain their existing dietary patterns throughout the study period.
Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.
Disqualifiers
BMI <18.5 or > 29.9 kg/m2
Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV/AIDS), or neurological condition or disease.
Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year.
History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
Trial design
Treatments tested in this trial
- Dietary Supplement - Placebo
- Geranylgeraniol (150 mg)
- Geranylgeraniol (300 mg)
Treatment groups
70 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov